Biochemical Basis and Dopamine Synthesis
The core problem in Parkinson's disease is the inability of brain structures to maintain adequate neurotransmitter levels. To understand this deficiency, we must review the normal biosynthetic pathway of this substance.
Biosynthesis occurs in several steps involving specific enzymes:
- Tyrosine serves as the initial substrate.
- Under the action of the enzyme tyrosine hydroxylase, it is converted into DOPA.
- Next, the enzyme DOPA decarboxylase cleaves off the carboxyl group, resulting in the formation of dopamine itself.
It is the disruption of this pathway or the degeneration of the cells where it takes place (Substantia nigra) that leads to the characteristic symptoms of the disease.
Neurotransmitter Inactivation Pathways
Normally, after dopamine fulfills its function, it must be degraded to prevent excessive receptor stimulation. Biochemical inactivation proceeds via two main pathways:
- Oxidative deamination. Catalyzed by the enzyme MAO (monoamine oxidase). This enzyme actively degrades dopamine directly within the synaptic cleft.
- Methylation. Carried out by the enzyme COMT (catechol-O-methyltransferase).
Understanding these degradation pathways is critical, as blocking these enzymes is a primary strategy in pharmacotherapy.
Logic of Pharmacotherapy
Since the core problem is dopamine deficiency, the initial thought might be to administer exogenous dopamine directly. However, free dopamine cannot cross the blood-brain barrier (BBB) from the bloodstream into the brain. Therefore, alternative biochemical routes are utilized.
Main drug classes:
- L-DOPA (Levodopa). A metabolic precursor of dopamine. Unlike the final product, levodopa successfully crosses the BBB. Once inside the brain tissue, it undergoes decarboxylation and is converted into active dopamine.
- Peripheral DOPA decarboxylase inhibitors (Carbidopa). If levodopa were converted into dopamine in the peripheral bloodstream, it would fail to enter the brain and would cause systemic side effects. Carbidopa blocks this process outside the CNS, sparing levodopa for the central nervous system.
- MAO inhibitors. Drugs that specifically target the MAO-B isoform. Inhibiting this enzyme slows down the degradation of dopamine in the synaptic cleft. Consequently, neurotransmitter concentration rises and its duration of action increases, effectively compensating for the initial deficit.
The Specific Role of Vitamin B6
Vitamin $B_6$ acts as an essential coenzyme for the decarboxylase enzyme that converts DOPA into dopamine.
It is used in moderate doses therapeutically. However, extreme caution is required: excess vitamin $B_6$ can sharply accelerate the peripheral breakdown of levodopa before it reaches the brain. To avoid this undesirable effect, vitamin $B_6$ must always be carefully regulated or combined with a decarboxylase inhibitor (such as carbidopa).